Public release date: 30-May-2013 [ | E-mail | Share ] Contact: Diana Quattrone diana.quattrone@fccc.edu 215-815-7828 Fox Chase Cancer Center CHICAGO, IL (May 28, 2013)A promising new therapy for the most common form of lung cancer appears to produce largely manageable side effects, and an ongoing clinical trial is determining whether the compound treats tumors more effectively than what's on the market, according research that scientists at Fox Chase Cancer Center will present at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1. "We're very excited about this drug," says Hossein Borghaei, DO, chief of thoracic medical oncology at Fox Chase. "I think if we learn how to use it appropriately, and manage the side effects effectively, it will be a good drug to have in our armamentarium." Lung cancer is the number one cause of death from cancer. Currently, patients with a metastatic form of the most common form of lung cancernon-small cell lung cancer (NSCLC)are treated with a combination of various chemotherapy drugs. If that fails, they are typically treated with a single agent. "We're trying to find a new option," says Borghaei, also the director of Lung Cancer Risk Assessment at Fox … Continue reading →

Attorney (866) 735-1102 Ext 511 Hemodialysis treatment can be an efficient way to replace loss of function in the kidneys; however it can also cause a number of side effects, such as low blood pressure, muscle cramps, itching, sleep problems, anemia, bone diseases and high blood pressure. Patients could also suffer from pericarditis, high potassium levels, stiffness and fluid in joints and depression. Many of these side effects are a result of the loss of electrolytes during the dialysis process. One treatment which is effective at reducing the side effects caused by loss of electrolytes is the use of Granulfo, a drug originally seen as a safe treatment option due to its lack of volatile chemicals. Unfortunately, GranuFlo also has some very dangerous side effects of its own, and was recalled in March of 2012 because it contains more of a substance which converts into bicarbonate in the human body. This additional bicarbonate can lead to heart problems and cause side effects including death, heart attack, low blood pressure, low potassium in the blood, low levels of oxygen in the blood, excessive carbon dioxide in the blood and cardiac arrhythmia (irregular heartbeat). In the early 2000s, GranuFlo was seen as … Continue reading →

(PRWEB) May 31, 2013 Diethylstilbestrol (DES), a synthetic hormone previously manufactured by several companies and formerly prescribed to pregnant women to prevent miscarriages and premature births, could potentially cause cancer in those womens children. The Rottenstein Law Group LLP acknowledges a Centers for Disease Control report of the struggles of "DES Daughters" with a series of life-threatening cancers related to their mothers use of the drug while pregnant. The firm maintains a DES Cancer Lawsuit Center at http://www.descancerlawsuit.com that features more details about lawsuits and the side effects of the drug. The CDC report* notes ongoing research into the manifestation of "clear cell adenocarcinoma, structural abnormalities in the reproductive organs, infertility and pregnancy complications." Rottenstein Law Group LLP Principal Rochelle Rottenstein comments on the research and how it relates to the communication she has received from those looking to file DES lawsuits. The first DES cancer lawsuits began as far back as the 1970s, but recently there have been more suits filed because of the drugs serious alleged lifelong side effects, Rottenstein said. Some side effects dont show up until later in the lives of so-called DES children and grandchildren. DES was prescribed to more than 10 million women from … Continue reading →

Public release date: 30-May-2013 [ | E-mail | Share ] Contact: Jackie Oberst NIMHPress@nih.gov 301-443-4536 NIH/National Institute of Mental Health GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects, reported a study funded by the National Institute of Mental Health (NIMH) that was published last month in Neuropsychopharmacology. Major depression affects about 10 percent of the adult population and is the second leading cause of disability in U.S. adults, according to the World Health Organization. Despite the availability of several different classes of antidepressant drugs such as selective serotonin reuptake inhibitors (SSRIs), 30 to 40 percent of adults are unresponsive to these medications. Moreover, SSRIs typically take weeks to work, which increases the risk for suicide. Enter NMDA (N-methyl-D-aspartate) receptor modulators. In the 1970s, researchers linked the receptors to learning and memory. Biotechnology and pharmaceutical companies in the 1980s attempted to apply chemical blockers to these receptors as a means to prevent stroke. But blocking these receptors led to the opposite effect--the rise of cardiovascular disease. Research in the field dampened until a glutamate receptor antagonist already approved for anesthesia, and known on the streets as "Special K," ketamine, made headlines in the … Continue reading →